TABLE 2.
Effect of the interventions on whole plasma CEC, apoB‐depleted CEC, ABCA1‐mediated CEC and passive diffusion
| Placebo | ATV | EVO | ATV + EVO | Main effect | Interaction | ||
|---|---|---|---|---|---|---|---|
| (n = 20) | (n = 22) | (n = 20) | (n = 19) | p‐value | p‐value | ||
| ATV | EVO | ATV vs EVO | |||||
| Whole plasma CEC (%) | |||||||
| Baseline | 18.1 (16.5–19.9) | 20.9 (19.0–23.0) | 19.5 (17.3–22.0) | 19.2 (16.9–21.7) | .003 | .001 | .67 |
| Week 8 | 17.2 (15.6–19.1) | 16.3 (14.5–18.3) | 15.4 (13.6–17.4) | 13.5 (12.1–15.2) | |||
| ApoB‐depleted CEC (%) | |||||||
| Baseline | 13.6 (12.8–14.4) | 13.9 (13.0–14.8) | 14.1 (12.7–15.7) | 13.6 (12.5–14.9) | .486 | .133 | .146 |
| Week 8 | 15.0 (14.2–15.8) | 15.3 (14.3–16.4) | 15.4 (14.2–16.6) | 14.3 (13.3–15.4) | |||
| ABCA1‐mediated CEC (%) | |||||||
| Baseline | 2.5 (1.8–3.6) | 2.9 (2.3–3.8) | 2.6 (1.8–3.6) | 2.2 (1.6–3.0) | .594 | .689 | .732 |
| Week 8 | 4.0 (3.4−4.7) | 4.5 (3.8–5.3) | 4.0 (3.4–4.7) | 3.7 (2.8–4.8) | |||
| Passive diffusion (%) | |||||||
| Baseline | 10.6 (10.0–11.2) | 10.6 (10.0–11.2) | 11.1 (10.0–12.3) | 11.1 (10.4–11.8) | .180 | .295 | .231 |
| Week 8 | 10.7 (10.0–11.4) | 10.7 (10.1–11.3) | 11.0 (10.4–11.5) | 10.2 (9.8–10.7) | |||
Data presented as geometric mean (95% CI). Bold values denote statistically significance of main effect of treatments compared with the placebo group using maximum‐likelihood random‐effects regression models.
Abbreviations: ABC, ATP‐binding cassette transporter; Apo, apolipoprotein; ATV, atorvastatin; CEC, cholesterol efflux capacity; EVO, evolocumab.